Exploring Advancements in Early Detection of Alzheimer's Disease with Molecular Assays and Animal Models

Ageing Research Reviews, Год журнала: 2024, Номер 100, С. 102411 - 102411

Опубликована: Июль 9, 2024

Язык: Английский

---

Anti-Cholinergic Effects of the Phenolic Extract from the Astragalus crenatus Plant: A Computational and Network Pharmacology Study

Pharmaceuticals, Год журнала: 2024, Номер 17(3), С. 348 - 348

Опубликована: Март 7, 2024

Investigations into cholinesterase inhibition have received attention from researchers in recent years for the treatment of Alzheimer’s disease. Cholinesterase enzymes, namely, acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), hold pivotal significance disease (AD) treatment. In this study, we utilized ethanolic extract Astragalus crenatus followed by liquid chromatography–electrospray ionization tandem mass spectrometry (LC-ESI-MS/MS) to separate identify at least 21 compounds extract. Rosmarinic acid exhibited highest concentration (96.675 ± 1.3 mg/g extract), succeeded hesperidin (79.613 1.2 hesperetin (75.102 1.4 rutin (68.156 1.6 chlorogenic (67.645 1.5 fisetin (66.647 2.3 hyperoside (63.173 extract). A. efficiently inhibited both AChE BChE activities a dosage-dependent manner. Molecular docking was employed scrutinize anticholinesterase mechanisms identified phytocompounds. Notably, network pharmacology analysis executed most efficacious compound. Based on binding energies, emerged as potent inhibitor against BChE, exhibiting scores −10.5 Kcal/mol −9.8 Kcal/mol, respectively. Due its dual activities, holds promise development novel therapeutics aimed neurological disorders, particularly AD.

Язык: Английский

---

Estrogen signalling and Alzheimer's disease: Decoding molecular mechanisms for therapeutic breakthrough

European Journal of Neuroscience, Год журнала: 2024, Номер 60(1), С. 3466 - 3490

Опубликована: Май 10, 2024

Abstract In females, Alzheimer's disease (AD) incidences increases as compared to males due estrogen deficiency after menopause. Estrogen therapy is the mainstay for menopause and associated complications. Estrogen, a hormone with multifaceted physiological functions, has been implicated in AD pathophysiology. plays crucial role amyloid precursor protein (APP) processing overall neuronal health by regulating various factors such brain‐derived neurotrophic factor (BDNF), intracellular calcium signalling, death domain‐associated (Daxx) translocation, glutamatergic excitotoxicity, Voltage‐Dependent Anion Channel, Insulin‐Like Growth Factor 1 Receptor, estrogen‐metabolising enzymes apolipoprotein E (ApoE) polymorphisms. All these impact physiology of postmenopausal women. replacement therapies play an important treatment strategy prevent However, use may lead increased risks breast cancer, venous thromboembolism cardiovascular disease. Various therapeutic approaches have used mitigate effects on AD. These include therapy, Selective Receptor Modulators (SERMs), Beta (ERβ)‐Selective Agonists, Transdermal Delivery, Localised Combination Therapies, Metabolism Modulation Alternative Estrogenic Compounds like genistein from soy, notable phytoestrogen plant sources. mechanism via which modulate women not explained earlier thoroughly. Present review will enlighten all molecular mechanisms Along‐with this, association between estrogen, ApoE polymorphisms also be discussed

Язык: Английский

---

Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease

Molecules, Год журнала: 2024, Номер 29(21), С. 5131 - 5131

Опубликована: Окт. 30, 2024

The most prevalent chronic neurodegenerative illness in the world is Alzheimer's disease (AD). It results mental symptoms including behavioral abnormalities and cognitive impairment, which have a substantial financial psychological impact on relatives of patients. review discusses various pathophysiological mechanisms contributing to AD, amyloid beta, tau protein, inflammation, other factors, while emphasizing need for effective disease-modifying therapeutics that alter progression rather than merely alleviating symptoms. This mainly covers medications are now being studied clinical trials or recently approved by FDA fall under treatment (DMT) category, alters targeting underlying biological DMTs focus improving patient outcomes slowing decline, enhancing neuroprotection, supporting neurogenesis. Additionally, amyloid-targeting therapies, tau-targeting neuroprotective others. evaluation specifically looked at studies FDA-approved novel Phase II III development were carried out between 2021 2024. A thorough US government database identified biologics small molecule drugs 14 agents I, 34 II, 11 might be completed 2028.

Язык: Английский

---

Unscrambling the cellular and molecular threads of Neuroplasticity: Insights into Alzheimer’s disease pathogenesis

Neuroscience, Год журнала: 2025, Номер unknown

Опубликована: Фев. 1, 2025

Язык: Английский

---

Plasma tryptophan levels are linked to hippocampal integrity and cognitive function in individuals with mild cognitive impairment

Brain Imaging and Behavior, Год журнала: 2025, Номер unknown

Опубликована: Март 4, 2025

Язык: Английский

---

The Exciting Frontier of Neuroplasticity: Innovations in Brain Health and Recovery

Journal of Behavioral and Brain Science, Год журнала: 2025, Номер 15(03), С. 47 - 80

Опубликована: Янв. 1, 2025

Язык: Английский

---

Transcriptomic and metabolomic changes might predict frailty in SAMP8 mice

Aging Cell, Год журнала: 2024, Номер 23(10)

Опубликована: Июль 3, 2024

Abstract Frailty is a geriatric, multi‐dimensional syndrome that reflects multisystem physiological change and transversal measure of reduced resilience to negative events. It characterized by weakness, frequent falls, cognitive decline, increased hospitalization dead represents risk factor for the development Alzheimer's disease (AD). The fact frailty recognized as reversible condition encourages identification earlier biomarkers timely predict prevent its occurrence. SAMP8 (Senescence‐Accelerated Mouse Prone‐8) mice represent most appropriate preclinical model this aim were used in study carry transcriptional metabolic analyses brain plasma, respectively, upon characterization at cognitive, motor, structural, neuropathological level 2.5, 6, 9 months age. At 2.5 months, started displaying memory deficits, muscle motor impairment. Functional alterations associated with neurodevelopmental deficiency neuronal density glial cell loss. Through transcriptomics, we identified specific genetic signatures well distinguishing 6 whereas plasma metabolomics allowed segregate from SAMR1 already age detecting constitutively lower levels acylcarnitines lipids all ages investigated correlating functional deficits signs. Our findings suggest central level, metabolomic changes might allow early assess frail leading dementia development, which paves foundation future investigation clinical setting.

Язык: Английский

---

Alzheimer’s Disease Pathology and Assistive Nanotheranostic Approaches for Its Therapeutic Interventions

International Journal of Molecular Sciences, Год журнала: 2024, Номер 25(17), С. 9690 - 9690

Опубликована: Сен. 7, 2024

Alzheimer’s disease (AD) still prevails and continues to increase indiscriminately throughout the 21st century, is thus responsible for depreciating quality of health associated sectors. AD a progressive neurodegenerative disorder marked by significant amassment beta-amyloid plaques neurofibrillary tangles near hippocampus, leading consequent loss cognitive abilities. Conventionally, amyloid tau hypotheses have been established as most prominent in providing detailed insight into pathogenesis revealing associative biomarkers intricately involved progression. Nanotheranostic deliberates rational thought toward designing efficacious nanosystems strategic endeavors diagnosis therapeutic implications. The exceeding advancements this field enable scientific community envisage conceptualize pharmacokinetic monitoring drug, sustained targeted drug delivery responses, fabrication anti-amyloid therapeutics, enhanced accumulation across blood–brain barrier (BBB), giving an optimistic approach towards personalized precision medicine. Current methods idealized on design bioengineering array nanoparticulate systems offer higher affinity neurocapillary endothelial cells BBB. They recently attracted intriguing attention early diagnostic measures taken manage progression disease. In article, we tend furnish comprehensive outlook, mechanism conventional pathogenesis, new findings. We also summarize shortcomings diagnostic, prognostic, approaches undertaken alleviate AD, unique window nanotheranostic without disregarding potential drawbacks, side effects, safety concerns.

Язык: Английский

---

ABORDAGENS TERAPÊUTICAS NA PREVENÇÃO DA PROGRESSÃO DA DOENÇA DE ALZHEIMER: UMA REVISÃO SISTEMÁTICA E META-ANÁLISE

Brazilian Journal of Implantology and Health Sciences, Год журнала: 2024, Номер 6(2), С. 1211 - 1227

Опубликована: Фев. 13, 2024

A abordagem terapêutica na DA está em constante evolução, abrangendo desde avanços farmacológicos até estratégias inovadoras que visam aprimorar a neuroplasticidade. Essa diversidade de opções terapêuticas reflete um esforço contínuo para oferecer tratamentos mais eficazes e abrangentes os afetados pela DA, destacando importância do desenvolvimento nesse cenário desafiador. Trata-se estudo cujo objetivo foi identificar abordagens destinadas à prevenção da progressão doença Alzheimer. Nesse sentido, desenvolvida uma revisão sistemática literatura, utilizando as bases dados Scielo, Lilacs Medline. Como conclusão, tem-se Alzheimer são diversas evolução. Embora haja promissores, especialmente farmacológicas como o uso anticorpos monoclonais, terapia genética nanotecnologia, desafios persistem, incluindo variação eficácia específicos necessidade contínua avaliação potenciais efeitos adversos longo prazo.

---